medical research, clinical care, education
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Advance healthcare discoveries through clinical and translational research at Columbia University Irving Medical Center.
Institutional clinical and translational research institute supported by grant funding.
Awarded $75 million to advance healthcare discoveries.
Advance healthcare discoveries through clinical and translational research at Columbia University Irving Medical Center.
Clinical and translational research infrastructure/program supported by grant funding.
Awarded $75 million to advance healthcare discoveries.
Evaluate calcium modification mechanisms and outcomes after orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified coronary lesions.
Prospective multicenter randomized ECLIPSE trial optical coherence tomography substudy comparing orbital atherectomy with balloon angioplasty before drug-eluting stent implantation; primary OCT endpoint was minimal stent area at the site of maximal calcification.
OCT substudy results reported in 2026 with 1-year target-vessel failure outcomes.
Orbital atherectomy produced greater calcium modification than balloon angioplasty, especially in thicker calcium, but minimal stent area and 1-year target-vessel failure rates were not significantly different between groups.
Compare long-term safety and efficacy of a drug-eluting resorbable scaffold versus percutaneous transluminal angioplasty in patients with chronic limb-threatening ischemia and infrapopliteal artery disease.
Randomized clinical trial assigning 261 patients 2:1 to Esprit BTK drug-eluting resorbable scaffold or balloon angioplasty/percutaneous transluminal angioplasty, with efficacy and safety endpoints including restenosis, revascularization, amputation, vessel occlusion, major adverse limb events, and perioperative death.
Three-year outcomes reported in 2026 after prior one- and two-year results.
At 3 years, the drug-eluting resorbable scaffold showed higher primary efficacy than angioplasty, lower binary restenosis, numerically lower clinically driven target lesion revascularization, high comparable limb salvage, and comparable safety.
Update terminology and best practices for clinical trial design, eligibility, endpoints, imaging, biomarkers, and patient-reported outcomes in advanced prostate cancer.
International expert committee process convened between 2016 and 2025 to formulate recommendations based on emerging evidence and clinical trial data in a biomarker context.
Recommendations published in 2026 for trial design and objectives in prostate cancer.
PCWG4 redefined disease-state and prior-therapy terminology, emphasized PET-defined disease and biomarker-based contexts of use, and recommended updated eligibility, response, delay/prevent endpoints, imaging intervals, and patient-reported outcome assessments.
Support basic biomedical science research and education, including long-shot basic research at Columbia medical school.
Research institute funded by a stated $400 million donation from P. Roy Vagelos.
Established with a $400 million gift supporting biomedical science research and education.
Compare calcium modification mechanisms and postprocedural stent expansion outcomes after orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified coronary lesions.
Prospective multicenter randomized ECLIPSE trial optical coherence tomography substudy comparing orbital atherectomy with balloon angioplasty before drug-eluting stent placement.
Reported OCT substudy findings from postprocedural imaging and 1-year target-vessel failure outcomes.
Orbital atherectomy produced greater calcium modification, especially in thicker calcium, but minimal stent area and 1-year target-vessel failure rates were not significantly different from balloon angioplasty.
Compare 3-year safety and efficacy of a drug-eluting resorbable scaffold versus percutaneous transluminal angioplasty in patients with chronic limb-threatening ischemia and infrapopliteal artery disease.
Randomized trial assigning 261 patients 2:1 to Esprit below-the-knee drug-eluting resorbable scaffold or percutaneous transluminal angioplasty, with efficacy and safety endpoints including vessel patency, restenosis, reintervention, limb events, and perioperative death.
Published 3-year outcomes from the LIFE-BTK trial.
At 3 years, the drug-eluting resorbable scaffold showed higher primary efficacy endpoint rates than angioplasty, lower binary restenosis, numerically lower clinically driven target lesion revascularization, and comparable limb salvage and safety.
Evaluate long-term safety and efficacy of the Esprit BTK drug-eluting resorbable scaffold versus percutaneous transluminal angioplasty in patients with chronic limb-threatening ischemia and infrapopliteal artery disease.
Multicenter randomized controlled trial assigning 261 patients 2:1 to drug-eluting resorbable scaffold or balloon angioplasty, with efficacy endpoints including freedom from above-ankle amputation, target vessel occlusion, clinically driven target lesion revascularization, and restenosis.
Reported 3-year outcomes from the LIFE-BTK trial.
At 3 years, drug-eluting resorbable scaffold treatment had higher primary efficacy than angioplasty, lower binary restenosis, numerically lower clinically driven target lesion revascularization, and comparable safety and limb salvage.
Update clinical trial terminology, eligibility, endpoint, imaging, patient-reported outcome, and biomarker-context recommendations for advanced prostate cancer.
International expert committee process convened from 2016 to 2025, integrating emerging evidence and clinical trial data with emphasis on PET imaging, molecular phenotyping, and biomarker-based context of use.
Published updated PCWG4 recommendations for advanced prostate cancer trial design.
Recommendations redefine disease-state terminology, eligibility criteria, response and delay/prevention endpoints, reassessment intervals, imaging criteria, and biomarker-based trial design considerations.